MolDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer

InVisionFirst (Inivata) plasma-based CGP is covered only for patients with advanced (Stage IIIB/IV) non-small cell lung cancer in limited scenarios: at diagnosis or at progression when testing for EGFR (SNVs/indels), ALK and ROS1 rearrangements, and BRAF SNVs is not available and tissue-based CGP is infeasible (QNS or biopsy contraindicated). It is also indicated for certain progression settings, including patients progressing on EGFR TKIs, and if plasma testing is negative or ctDNA is insufficient, tissue-based genotyping should be pursued when feasible.

"Patient has advanced (Stage IIIB or Stage IV) non-small cell lung cancer (NSCLC)."

Sign up to see full coverage criteria, indications, and limitations.